HNK-1, Trk-A, H-Ras, GRP78, GRP75 and calreticulin, are biologic factors already identified that predicted a favorable outcome for NB patients associated with the differentiation or regression of NB cells at early clinical stages [9], [10]. The gene discussed is HSPA9; the disease is neuroblastoma.